Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

This study is currently recruiting participants.
Verified June 2013 by National Institutes of Health Clinical Center (CC)
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
First received: February 12, 2011
Last updated: March 14, 2014
Last verified: June 2013


- Ferumoxytol is an approved iron replacement therapy agent that has some potential for use as a contrast agent in imaging studies of the lymph system, especially involving lymph nodes that have been affected by cancer. Ferumoxytol is taken up by normal lymph nodes, but excluded from cancerous lymph node tissue. Because Ferumoxytol has not yet been approved for use as an imaging agent, researchers are interested in testing its effectiveness as a contrast agent for studies of normal lymph tissue and cancer tissue in lymph nodes of individuals with prostate cancer.


- To evaluate the safety and effectiveness of Ferumoxytol as a contrast agent in individuals who are scheduled to have prostate removal surgery to treat prostate cancer.


- Men at least 18 years of age who have been diagnosed with prostate cancer and are scheduled to have surgery to remove the prostate and surrounding lymph nodes.


  • Participants will be screened with a full medical history and physical examination, blood and urine tests, and tumor imaging studies.
  • Participants will have a magnetic resonance imaging (MRI) scan to provide baseline images for the study.
  • Participants will receive an injection of Ferumoxytol and will return for another MRI scan on the following day (around 24 hours later).
  • Some participants may have a third MRI scan 48 hours after the initial injection of Ferumoxytol. This third MRI scan is optional and not required by the study.
  • Although the scanning and followup portion of the study will last only a few days, participants will be considered to be enrolled on the study until after the prostate removal surgery.

Condition Intervention Phase
Prostate Cancer
Drug: Ferumoxytol
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • To determine the optimal dose of Ferumoxytol for enhancing lymph nodes in patients with prostate cancer.

Secondary Outcome Measures:
  • To determine the safety of Ferumoxytol in the setting of presumed localized prostate cancer.

Estimated Enrollment: 23
Study Start Date: January 2011
Intervention Details:
    Drug: Ferumoxytol
  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
  • Subject must be male and be greater than or equal to 18 years old.
  • Subject must have a histologically confirmed diagnosis of prostate cancer.
  • Subjects enrolling in the lymph node involvement subgroup must have imaging evidence of lymph node involvement (with a size of greater than or equal to 1.5 cm).
  • Subject must have Eastern Cooperative Oncology Group Performance score less than or equal to 2.

Subjects in the dose finding cohorts must be scheduled to undergo prostatectomy for presumed prostate cancer.

-Subjects must be scheduled to undergo prostatectomy for presumed prostate cancer


  • Subjects with known hypersensitivity and allergy to iron
  • Subjects with evidence of iron overload with a pre-study ferritin level greater than 370 ng/ml and percent saturation of transferrin level greater than 40%. Patients with lab values above these limits may be included in the study if documented hematology consultation rules out hemochromatosis.
  • Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results
  • Subjects with severe claustrophobia unresponsive to oral anxiolytics
  • Subjects with contraindications to MRI
  • Subjects weighing > 136 kg (weight limit for scanner table)
  • Subjects with pacemakers, cerebral aneurysm clips, shrapnel injury, or other implanted electronic devices or metal not compatible with MRI.
  • Subjects with abnormal liver function tests suggesting liver dysfunction (AST and ALT > 2 times the upper limits of normal; total bilirubin, of > 2 times the upper limits of normal or > 3.0 mg/dl in patients with Gilbert s syndrome).
  • Subjects with other medical conditions deemed by the principle investigator (or associates) or the sponsor to make the subject ineligible for protocol procedures.


  • Members of all races and ethnic groups are eligible for this trial.
  • Women are excluded from this trial as prostate cancer does not occur in females.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01296139

Contact: Yolanda McKinney, R.N. (301) 443-6913 ymckinney@mail.nih.gov
Contact: Peter L Choyke, M.D. (301) 402-8409 pchoyke@mail.nih.gov

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    (888) NCI-1937      
Sponsors and Collaborators
Principal Investigator: Peter L Choyke, M.D. National Cancer Institute (NCI)
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT01296139     History of Changes
Other Study ID Numbers: 110098, 11-C-0098
Study First Received: February 12, 2011
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Non-Cutaneous Malignancy
Metastatic Prostate Cancer
Imaging Study
Magnetic Resonance Imaging
Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 15, 2014